We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Clinuvel Pharmaceuticals is a biotechnology business based in Australia. Clinuvel Pharmaceuticals shares (CUV) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Clinuvel Pharmaceuticals has a trailing 12-month revenue of around $56.9 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
Best overall broker
Our top pick for
Best low-cost broker
| 52-week range | $13.16 - $44.67 |
|---|---|
| 50-day moving average | $15.8922 |
| 200-day moving average | $25.5295 |
| Target price | $28.55 |
| PE ratio | 31.617 |
| Dividend yield | $0.025 (0.18%) |
| Earnings per share (TTM) | $0.47 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$16.46
| 1 week (2022-06-17) | 13.99% |
|---|---|
| 1 month (2022-05-25) | 6.74% |
| 3 months (2022-03-25) | -10.25% |
| 6 months (2021-12-24) | -42.43% |
| 1 year (2021-06-25) | -42.18% |
|---|---|
| 2 years (2020-06-25) | -35.27% |
| 3 years (2019-06-25) | -54.23% |
| 5 years (2017-06-23) | 155.59% |
Valuing Clinuvel Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Clinuvel Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Clinuvel Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 32x. In other words, Clinuvel Pharmaceuticals shares trade at around 32x recent earnings.
That's comparable to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14).
Clinuvel Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $31.3 million (£0.0 million).
The EBITDA is a measure of a Clinuvel Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $56.9 million |
|---|---|
| Operating margin TTM | 54.23% |
| Gross profit TTM | $41.2 million |
| Return on assets TTM | 18.94% |
| Return on equity TTM | 26.01% |
| Profit margin | 42.4% |
| Book value | 2.171 |
| Market capitalisation | $734.2 million |
TTM: trailing 12 months
Dividend payout ratio: 5.43% of net profits
Recently Clinuvel Pharmaceuticals has paid out, on average, around 5.43% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.18% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Clinuvel Pharmaceuticals shareholders could enjoy a 0.18% return on their shares, in the form of dividend payments. In Clinuvel Pharmaceuticals's case, that would currently equate to about A$0.025 per share.
While Clinuvel Pharmaceuticals's payout ratio might seem low, this can signify that Clinuvel Pharmaceuticals is investing more in its future growth.
The latest dividend was paid out to all shareholders who bought their shares by 2 September 2021 (the "ex-dividend date").
Clinuvel Pharmaceuticals's shares were split on a 1:10 basis on 12 November 2010. So if you had owned 10 shares the day before the split, the next day you would own 1 share. This wouldn't directly have changed the overall worth of your Clinuvel Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Clinuvel Pharmaceuticals shares which in turn could have impacted Clinuvel Pharmaceuticals's share price.
Over the last 12 months, Clinuvel Pharmaceuticals's shares have ranged in value from as little as $13.16 up to $44.67. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Clinuvel Pharmaceuticals's is 0.767. This would suggest that Clinuvel Pharmaceuticals's shares are less volatile than average (for this exchange).
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
Steps to owning and managing Nexgen Energy shares.
Steps to owning and managing Keypath Education shares.
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
What's the best way to invest money in Australia? Find out about robo advisors, index funds, cryptocurrency and more in this guide.
Steps to owning and managing EBR Systems shares.
Steps to owning and managing 5E Advanced Materials shares.
Steps to owning and managing Leo lithium shares.
Steps to owning and managing Besra Gold shares.
Steps to owning and managing The Lottery Corporation shares.
Steps to owning and managing Endeavour Group shares.
